The birthday card the grandson shared is the last one his grandfather wrote before dementia made writing impossible. Its value lies in preserving his familiar handwriting and personal connection, not in proving when or why his abilities changed. Dementia is an umbrella term for cognitive decline severe enough to disrupt daily life, rather than one specific disease. It can affect memory, thinking, behavior, reading, and writing, according to the National Institute on Aging.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What can the birthday card reveal?
- Is declining writing a sign of dementia?
- What should a family do after noticing changes?
- Can a blood test diagnose Alzheimer's?
- What can current treatment realistically do?
What can the birthday card reveal?
The card documents something meaningful: his grandfather could still compose and write a birthday message at that moment. For the family, it may mark a boundary between what remained possible and what dementia later took away. Changes could include shorter messages, repeated words, incomplete sentences, or increasing difficulty forming letters.
However, handwriting and composition vary for many reasons. Even a clear decline cannot identify a dementia type or establish a diagnosis. The safest reading is emotional, not clinical. The card preserves the grandfather's expression at a particular time, while its medical meaning remains limited without a broader history and assessment.
Is declining writing a sign of dementia?
Difficulty writing can be consistent with dementia-related changes in language or thinking. It becomes more concerning when it appears alongside memory loss, behavioral changes, or trouble managing ordinary daily activities. Yet writing difficulty is nonspecific.
Cognitive changes can also result from medication effects, depression, infection or delirium, metabolic or endocrine conditions, tumors, or vitamin deficiencies. Some of these causes may improve with treatment, the National Institute on Aging explains. A birthday card therefore cannot distinguish Alzheimer's disease from another dementia or a potentially treatable condition. It can serve as one dated example in a larger pattern.
What should a family do after noticing changes?
New problems with language, memory, or daily functioning warrant a clinical assessment. A primary-care clinician may refer the person to a neurologist, geriatrician, neuropsychologist, or geriatric psychiatrist.
Families can prepare useful context before the appointment: A timeline matters more than a single imperfect card. It helps the clinician understand whether the problem is new, progressive, or connected to another change in health.
- Note when the changes first appeared and whether they are worsening.
- Record examples involving conversation, reading, writing, memory, or routine tasks.
- Bring a current medication list and describe recent health changes.
- Preserve dated writing samples without treating any one sample as proof.
- Ask whether specialist evaluation is appropriate.
Can a blood test diagnose Alzheimer's?
The FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 blood test on May 16, 2025. It is intended for symptomatic adults aged 55 or older who are being evaluated in specialized care, according to the FDA clearance notice. The test is not approved as a stand-alone diagnosis.
False results can occur, so clinicians must interpret it alongside symptoms and other clinical information. It also addresses Alzheimer's disease, not every cause of dementia. A change in handwriting alone neither establishes eligibility for the test nor shows that Alzheimer's caused the change.
What can current treatment realistically do?
The FDA approved Kisunla, or donanemab-azbt, as an intravenous infusion given every four weeks for Alzheimer's disease. Treatment should begin in people with mild cognitive impairment or mild dementia, matching the population studied—not people with every dementia type or advanced disease. In a 1,736-person trial, the FDA reported statistically significant slowing of decline at 76 weeks, with a 2.92-point difference on the iADRS trial scale.
The treatment did not restore abilities already lost. It also carries a boxed warning for ARIA, a potentially serious imaging abnormality that has included rare serious events, as detailed in the FDA approval notice. Families considering treatment should first confirm the diagnosis and disease stage with an appropriate clinician. A drug that slowed decline in early Alzheimer's should not be presented as a way to recover writing or other abilities dementia has already taken.
